FGFrol A. Gugnin

Frol A. Gugnin

*This is an algorithmically generated author record based on publicly available information.

Frol A. Gugnin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Robotic surgery for endometrial cancer in patients with high body mass index: A retrospective analysis of the Department of Gynecologic Oncology at S.S. Yudin City Clinical Hospital (Moscow)

    by D. O. Utkin, A. U. Adzhieva, A. V. Lazarchuk, A. D. Sidorov, F. A. Gugnin, S. V. Bulgakova, A. M. Kvartskhava, A. G. Solopova, V. O. Bitsadze, A. D. Makatsariya, et al.

    Introduction . Obesity is one of the major risk factors for endometrial cancer and significantly complicates surgical treatment due to technical challenges, limited visualization of the operative field, and an increased risk of perioperative complications. Robotic-assisted surgery has emerged as a promising minimally invasive approach capable to overcome these limitations. Aim . To evaluate the impact of obesity severity on perioperative outcomes of robotic-assisted surgery in patients with endometrial cancer. Materials and methods . This retrospective single-center study included 102 patients with endometrial cancer and class I–III obesity who underwent robotic-assisted surgery. Patients were stratified into three groups according to class of obesity. The operative time, estimated blood loss, length of postoperative hospital stay, and perioperative complications were assessed. Results . No statistically significant differences in operative time were observed among the BMI groups (p >0.05). Patients with class III obesity had higher intraoperative blood loss compared with those with class I and II obesity; however, the absolute blood loss remained low. In addition, morbidly obese patients had a significantly longer postoperative hospital stay, with a median of 4 days versus 2 days in the other groups. Perioperative complications occurred in 2 patients (1.96 %) and did not require reoperation. Conclusion . Robotic-assisted surgery is a safe and effective treatment modality for endometrial cancer in patients with varying class of obesity.

  • Open Access

    Serum levels of the soluble transmembrane adhesion molecule P-cadherin in healthy women and in patients with malignant and benign ovarian tumors

    by Nikolay E. Kushlinskii, Olga V. Kovaleva, Alexei N. Gratchev, Svetlana E. Kulikova, Frol A. Gugnin, Svetlana Y. Nezhdanova, Dmitry A. Tsekatunov, Irina B. Ryzhavskaya, Dmitry N. Kushlinskiy, Natalya N. Zybina, et al.

    Background: Cadherins are calcium-dependent transmembrane glycoproteins whose extracellular domains mediate homophilic intercellular interactions. Their soluble forms (s-cadherins), generated through proteolytic cleavage of transmembrane proteins or alternative mRNA splicing, are not anchored in the cell membrane and circulate in the extracellular space or peripheral blood. In the context of carcinogenesis, the role of P-cadherin remains a matter of debate: some studies associate P-cadherin with tumor growth suppression, while others indicate its tumor-promoting properties. Publications on the significance of the soluble P-cadherin in various disorders are scarce. Aim: To perform a comparative analysis of serum sP-cadherin levels in healthy women and in patients with malignant and benign ovarian tumors to assess the clinical significance of the marker. Methods: The retrospective study included 56 patients with epithelial malignant ovarian tumors (median age 57 years), 10 patients with benign ovarian tumors (median age 55 years), and 11 healthy women (median age 56 years) who underwent examination and treatment from 2023 to 2024 in three oncology clinics. Serum levels of sP-cadherin before the initiation of specific treatment were determined with the Human P-Cadherin ELISA Kit (RayBiotech, USA). Results: In the ovarian cancer group, the majority of the patients had the serous type of the tumor (n = 46, 82%), stage III to IV of the disease (n = 45, 80%), T3 and T4 tumors (n = 42, 75%), mostly without regional (N0: n = 41, 73%) and distant metastases (M0: n = 43, 77%). The results of the ROC analysis showed that serum levels of the soluble P-cadherin could not be used as a reliable diagnostic criterion for ovarian malignancies: the area under the curve (AUC) was 0.793 (confidence interval 0.671 to 0.915; p = 0.002). At the optimal cut-off value of 3.01 ng/mL, the test’s sensitivity and specificity were 77% and 73%, respectively. The serum sP-cadherin levels did not show a significant correlation with the key clinical and morphological characteristics of ovarian cancer. Conclusion: Patients with ovarian cancer have an increased serum sP-cadherin level. Further research on this glycoprotein to assess its role in disease outcomes and chemotherapy efficacy is expedient.


  • Open Access

    Clinical and laboratory significance of soluble claudin-5 and VEGF in ovarian cancer

    by N. E. Kushlinskii, S. E. Kulikova, F. A. Gugnin, S. Yu. Nezhdanova, A. N. Gratchev, D. O. Utkin, D. A. Tsekatunov, I. B. Ryzhavskaya, D. N. Kushlinskiy, E. S. Gershtein, et al.

    Introduction. Claudin 5 is belongs to a family of transmembrane proteins mediating formation of tight junctions between cells, maintenance of cell polarity in epithelial and endothelial layers, regulation of cell membrane permeability, and control of signal transduction inside the cells. Results of a small number of studies show that vascular endothelial growth factor (VEGF) also affects formation of tight junctions, in particular through regulation of claudin 5 expression. In addition to their physiological functions, claudin 5 and VEGF play an important role in pathogenesis of various diseases including malignant neoplasms.Aim. To study the levels of claudin 5 and VEGF in serum of patients with ovarian cancer and evaluate their clinical significance.Materials and methods. In total, 123 patients with ovarian cancer (median age 54 years) and 32 control group healthy women (median age 54 years) were examined. Claudin 5 and VEGF levels in serum were measured prior to treatment using Human CLDN5 (Claudin 5) ELISA Kit (Elabscience, China) and Human VEGF Immunoassay (Quantikine®, RD Systems, uSA) in accordance with the manufacturer’s instructions. Statistical analysis of the obtained data was performed using the GraphPad Prizm v. 10 software. The values were compared and their correlations quantified using nonparametric Mann–Whitney, Kruskal–Wallis tests and Spearman’s rank correlation coefficient. Overall survival was analyzed using the Kaplan–Meier method.Results. Claudin 5 was found in serum of 97 % of patients with ovarian cancer and 94 % of the control group women. Median (1st quartile (Q1) – 3rd quartile (Q3)) level of claudin 5 in serum of healthy women was 0.77 (0.48–1.17) ng/mL, patients with ovarian cancer – 0.95 (0.43–1.77) mg/mL. ROC analysis of informational value of claudin 5 in ovarian cancer showed unsatisfactory diagnostic accuracy of the model (area under the ROC curve (AuC) 0.613 (95 % confidence interval (CI) 0.513–0.713); p = 0.049): for median threshold value of 0.95 ng/mL the assay had sensitivity of 50 % and specificity of 60 %. VEGF was found in all patients with ovarian cancer and healthy women; median (Q1–Q3) VEGF level in serum of healthy women was 45.6 (13.3–89.09) pg/mL and was statistically significantly lower than in patients with ovarian cancer: 274.7 ng/mL (199.0–472.5). ROC analysis for ovarian cancer showed good diagnostic accuracy of the model (AuC 0.942 (95 % CI 0.886–0.997); p 0.0001) which allows to use serum VEGF level as a diagnostic criterion. The best results for sensitivity and specificity (71 and 100 %, respectively) were obtained at VEGF threshold level of 226.2 pg/mL. Serum claudin 5 and VEGF levels are associated with ovarian cancer progression. However, claudin 5 and VEGF are not statistically significant prognostic markers for this disease.Conclusion. Serum levels of VEGF and claudin 5 in patients with ovarian cancer are significantly higher than in control group women and positively correlate with each other. Additionally, VEGF has relatively good diagnostic characteristics compared to healthy women of the control group. VEGF and claudin 5 levels are associated with the presence of distant metastases which points at their potential role in tumor progression. However, at this research stage, these markers cannot be recommended as diagnostic or prognostic criteria in ovarian cancer and require further study.